Percheron Therapeutics Ltd (PER)

Sydney
Currency in AUD
0.010
0.000(0.00%)
Closed·
PER Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PER is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0100.010
52 wk Range
0.0050.140
Key Statistics
Edit
Bid/Ask
0.01 / 0.011
Prev. Close
0.01
Open
0.01
Day's Range
0.01-0.01
52 wk Range
0.005-0.14
Volume
592.37K
Average Volume (3m)
2.09M
1-Year Change
-89.13%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PER Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Percheron Therapeutics Ltd News & Analysis

Show more

Percheron Therapeutics Ltd Company Profile

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Compare PER to Peers and Sector

Metrics to compare
PER
Peers
Sector
Relationship
P/E Ratio
−0.7x−5.1x−0.5x
PEG Ratio
0.31−0.020.00
Price/Book
0.7x3.9x2.6x
Price / LTM Sales
5.7x11.2x3.1x
Upside (Analyst Target)
0.0%312.5%51.1%
Fair Value Upside
Unlock15.4%8.9%Unlock

Earnings

Latest Release
Feb 19, 2025
EPS / Forecast
-0.01 / -1.40
Revenue / Forecast
151.79K / --
EPS Revisions
Last 90 days

PER Income Statement

FAQ

What Is the Percheron Therapeutics (PER) Stock Price Today?

The Percheron Therapeutics stock price today is 0.01

What Stock Exchange Does Percheron Therapeutics Trade On?

Percheron Therapeutics is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Percheron Therapeutics?

The stock symbol for Percheron Therapeutics is "PER."

What Is the Percheron Therapeutics Market Cap?

As of today, Percheron Therapeutics market cap is 10.87M.

What Is Percheron Therapeutics's Earnings Per Share (TTM)?

The Percheron Therapeutics EPS (TTM) is -0.02.

From a Technical Analysis Perspective, Is PER a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Percheron Therapeutics Stock Split?

Percheron Therapeutics has split 3 times.

How Many Employees Does Percheron Therapeutics Have?

Percheron Therapeutics has 8 employees.

What is the current trading status of Percheron Therapeutics (PER)?

As of 15 June 2025, Percheron Therapeutics (PER) is trading at a price of 0.01, with a previous close of 0.01. The stock has fluctuated within a day range of 0.01 to 0.01, while its 52-week range spans from 0.01 to 0.14.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.